Brainstorm Cell Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Brainstorm Cell Therapeutics

12/05/2023 19:32

* Brainstorm Cell Therapeutics Inc  BCLI.OQ   BCLI.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 15. 
    * 
    * ​Refinitiv's mean analyst estimate for Brainstorm Cell
Therapeutics Inc is for a loss of 16 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Brainstorm
Cell
Therapeutics Inc is $15​, above​ its last closing price
of $2.86. ​​​

This summary was machine generated May 12 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated